Pfizer Inc. Stock

At first glance, Pfizer (NYSE: PFE) looks like a great stock to buy. The company has a reliable dividend program and regularly raises its payouts, boasting a 6.8% forward yield, well above the S&P

When it comes to high-yield dividend stocks, it's not a matter of quantity, but of quality. There are numerous stocks with forward dividend yields of 5% or higher, but many of them are firmly in the

Pfizer (NYSE: PFE) has a shockingly high dividend yield of 6.8%. The S&P 500 Index (SNPINDEX: ^GSPC) has a 1% yield, and the average pharmaceutical stock's yield is roughly 1.5%. Given that huge

BioNTech (NASDAQ: BNTX) rose to prominence several years ago thanks to its role in the coronavirus market. The company developed Comirnaty, one of the best-selling COVID-19 vaccines, with Pfizer

We can separate high-yield dividend stocks into two broad categories. The first group consists of companies with stable businesses that generate consistent cash flow and are very likely to continue

Pfizer (NYSE: PFE) has not performed well in recent years, as demand for its coronavirus products has plummeted. Meanwhile, several of the company's newer launches haven't made much of an impact on

Shares of Pfizer (NYSE: PFE) have fallen more than 50% from their late 2021 highs. That massive drawdown has pushed the dividend yield up to a historically high 6.9%. To put that yield into

The big reason to buy Pfizer (NYSE: PFE) right now is its huge 7% dividend yield. To put that into perspective, the S&P 500 index (SNPINDEX: ^GSPC) yields a tiny 1%, and the average pharmaceutical

Broader equities have performed so well in recent years that the dividends companies pay haven't kept pace. As a result, the S&P 500's average yield is just 1.1% right now. Thankfully, it's possible

A high-yielding dividend may sound great for investors, but it can be a double-edged sword: when it's too high, investors start to worry about its safety. That's a big part of the reason why Pfizer

Many investors often associate high-yield dividend stocks with high risk. This concern makes sense, given how many high yielders end up turning into "yield traps," where a company cuts or suspends

Humans are very bad at taking medications. By some estimates, adherence to long-term chronic medication treatment plans is only around 50%. This is a big issue for GLP-1 weight-loss drugs, which

Dividend investing is a proven way to earn above-average long-term returns. That's why top dividend stocks often attract large crowds of investors and trade at a premium. However, it's possible to

It's hard not to love high dividend yields. Who doesn't want more dividends for their money? Pfizer (NYSE: PFE) and its current yield of 7% will certainly grab your attention.

But remember that the

Pfizer's (NYSE: PFE) shares have significantly underperformed broader equities over the past three years. The company's reliance on its coronavirus portfolio has been a weakness, as vaccination

Although its growth rate has been cause for concern for investors in recent years, Pfizer (NYSE: PFE) is a stock that I don't think you should count out right now. The company is in the midst of a

Pfizer's (NYSE: PFE) shares have lost more than 50% of their value since late 2021 due to poor financial results. The company has tried to bounce back. Notably, it has expanded its pipeline through